抑那通在前列腺癌内分泌治疗中的临床意义

Clinical evalution of Enantone in the treatment of prostate cancer

目的为提高晚期前列腺癌内分泌治疗效果，１９９０年７月～１９９２年７月间对１７例前列腺癌患者进行了抑那通（药物除睾）的临床观察。方法随访３～５年获得可评价资料１６例病例，采用免疫酶联法测定ＰＳＡ变化，放免法检测性激素水平，用Ｉ－ＰＳＳ表调查排尿及生活质量，对前列腺及转移病灶、全身状况的变化进行对比观察。结果抑那通治疗后睾酮降至去势水平（Ｐ＜０．０１），前列腺特异抗原及其他肿瘤标记物提示反应性良好，症状及全身状况明显改善。结论每月注射一次抑那通，如果与抗男性素剂联合使用可获得更安全有效的治疗效果。

Objective In order to improve the effect of hormone treatment for prostate cancer, a total of 17 such patients were treated with Enantone(chemical castration) from July 1990 to July 1992. Methods In the control group, 16 evaluable patients who were followed for 3 to 5 years, PSA was determined with ELISA. Commercial kit was used for determination of T, LH and FSH. Prostate lesion and metastasis and patient's status was eximination in the follow up. Results Enantone was ableto suppress plasma testosterone concentration to the condition of castration during treatment ( P < 0.01 ). PSA and other markers also responded well. Significant improvement in performance status, micturition problems and general well being was reported. Conclusion The once a month administration of Enantone combined with flutamide is effective in the managemant of advanced prostate cancer with acceptable side effects.